Fresenius Kabi USA announced the launch of Acetylcysteine Solution 20% in a 10mL vial for inhalation or oral administration. 

Acetylcysteine Solution is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease, acute bronchopulmonary disease, pulmonary complications of cystic fibrosis, tracheostomy care, pulmonary complications associated with surgery, use during anesthesia, post-traumatic chest conditions, atelectasis due to mucous obstruction, diagnostic bronchial studies. Inhalation therapy reduces the viscosity of mucus, thinning mucus secretions.

RELATED: Respiratory Disorders Resource Center

When administered orally, it is indicated as an antidote to prevent or lessen hepatic injury following acetaminophen overdose.

Acetylcysteine Solution has been on the FDA and the American Society of Health-System Pharmacists (ASHP) drug shortage lists since 2011. In 2012, Fresenius Kabi introduced Acetylcysteine Solution 20% concentration in 30mL vials and earlier this year introduced Acetylcysteine Injection.

Acetylcysteine Solution, 20% is available in 10mL and 30mL vials for inhalation or oral administration.

For more information call (847) 550-7121 or visit